Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

NCT ID: NCT00859495

Last Updated: 2020-08-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2012-02-29

Brief Summary

The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous chemotherapy, and local P-32 irradiation for malignant pleural mesothelioma.

Detailed Description

Current surgical and/or chemotherapeutic approaches for malignant pleural mesothelioma are unsatisfactory and have not been shown to significantly prolong survival, and often lead to worsened pulmonary function and quality of life. We will investigate whether a prospective trial of trimodal (surgery, pleural chemotherapy, and pleural radiation) therapy can improve the overall 1 year survival in patients with malignant pleural mesothelioma. The proposed treatment will include exploratory thoracoscopy, placement of Mediport catheters into the pleural space, intraoperative chemotherapy, repeated intraperitoneal chemotherapy, and intrapleural instillation of radioactive P32 to radiate the pleural surfaces. In addition, because this study is randomized, half the patients will receive an additional three intravenous systemic chemotherapy treatments of cisplatin and pemetrexed (Alimta) in tandem with their intrapleural chemotherapy (weeks 3, 6, and 9 only).

The potential significance of this research is that such treatment may render it less necessary to surgically remove the affected lungs in whole or in part, in order to achieve significant disease cytoreduction. We hope to alter the currently accepted paradigm that major lung surgery is an inescapable component of such treatment, and advance the concept that a combination of judicious preparative surgery, systemic chemotherapy, and locoregional drug treatment of the pleural surfaces may offer the best hope for prolongation of survival with intact lung function.

Conditions

Pleural Mesothelioma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Multimodal lung sparing regimen

Intrapleural chemotherapy plus systemic chemotherapy:

Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.

Group Type: EXPERIMENTAL

Doxorubicin

Intervention Type: DRUG

A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.

Cisplatin

Intervention Type: DRUG

Platinum-based antineoplastic

Pemetrexed

Intervention Type: DRUG

Folate Analog Metabolic Inhibitor

Radiotherapy

Intervention Type: RADIATION

Standard procedure given 3 weeks after last dose of chemotherapy

Interventions

Doxorubicin

A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.

Intervention Type: DRUG

Cisplatin

Platinum-based antineoplastic

Intervention Type: DRUG

Pemetrexed

Folate Analog Metabolic Inhibitor

Intervention Type: DRUG

Radiotherapy

Standard procedure given 3 weeks after last dose of chemotherapy

Intervention Type: RADIATION

Other Intervention Names

Doxil; Cisplatinum; Platinol; Alimta; Intrapleural radiotherapy with P-32

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed malignant mesothelioma, < 20% sarcomatoid type
• No radiographic or other imaging evidence of Stage IV (cardiac, mediastinal, peritoneal, other distant) disease.
• Ineligible for other high priority national or institutional study.
• Age >18 years [to physiologic 75 years].
• Life expectancy > 3 months.
• Performance status, PS 0-2 [Karnofsky Performance Status, KPS=70-100 %].
• Prior therapy allowed (one prior systemic regimen) meeting the following parameters.
• No prior chest radiation therapy within 6 weeks of treatment
• No prior chemotherapy regimens within four weeks of treatment
• Non pregnant, non-lactating. (serum HCG test will be performed in patients in whom there is a possibility of pregnancy.)
• Required initial laboratory data/clinical parameters (see also Sec. 8.0) White cell count: >3000/ul. Platelet count: >100,000/ul. Creatinine clearance: ≥ 45 ml/min Bilirubin: < 2 x ULN SGOT or SGPT: < 2 x ULN
• Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
• No other coexistent malignancy. However, curatively treated or fully controlled solid tumors (other than mesothelioma) may be eligible if in the judgement of the PI, the benefit of treatment outweighs the risk.
• No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection, congestive heart failure, angina pectoris, cardiac arrhythmia(s), or uncontrolled hypertension). HIV status or other severe illnesses will be assessed using medical records.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert N Taub, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Columbia University Medical Center

New York, New York, United States

Countries

United States

Other Identifiers

AAAB9658

Identifier Type: -

Identifier Source: org_study_id